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Background: Previous investigation has demonstrated that CD4+ T cells play a crucial role in effective immunity
against Helicobacter pylori (H.pylori) infection. It has been well proved that Lpp20 is one of major protective antigens
that induce immune responses after H.pylori invades host. Therefore it is valuable to identify CD4+ T cell epitopes
on Lpp20, which is uncharacterized.
Methods: Putative epitopes of H-2d restricted CD4+ T cell on Lpp20 of H.pylori were predicted by the SYFPEITHI
algorithm and then eight hypothetical epitope peptides were synthesized. After BALB/c mice were primed with
recombinant Lpp20, splenic CD4+ T cells were isolated and stimulated with synthesized peptides to measure T cell
proliferation and MHC restriction. Cytokine profile was determined by ELISA and real-time PCR. Two identified
epitopes were used to immunize mice to investigate CD4+ T cell response by flow cytometry.
Results: Two of eight peptides were able to stimulate CD4+ T cell proliferation and were mapped to residues
83-97aa and 58-72aa on Lpp20 respectively. These two peptides additively stimulated Th1 cells to secrete IFN-γ.
The percentage of CD4+ T cell from mice immunized with two identified epitopes respectively was higher than the
control group.
Conclusion: The identification and characterization of two CD4+ T cell epitopes of Lpp20 helps understand the
protective immunity of Lpp20 in H.pylori infection and design effective epitope vaccines against H.pylori.
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Helicobacter pylori(H.pylori) is a gram-negative bacilli,
which colonizes the stomach and causes 50% infection
of the population worldwide. Chronic infection with H.
pylori is the main cause of various gastroduodenal dis-
eases such as gastritis, peptic ulcer and is also a risk fac-
tor for gastric adenocarcinoma and lymphoma. In
general, the host elicits robust immune response to H.
pylori infection. However, the infection is often persist-
ent and lasts for very long time, suggesting that H.pylori
may evade both innate and adaptive immune responses.
The mechanism of protection against H.pylori infec-
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reproduction in any medium, provided the orevidences to support a pivotal role of CD4+ T helper
cells (Th cells) in the immune response against H.pyori
infection [1]. Th cells are activated when the peptide
antigens are presented by MHC II molecules, which are
expressed on the surface of antigen presenting cells
(APCs). Once activated, Th cells are divided rapidly and
secrete cytokines to regulate the active immune re-
sponse. When MHC II mutant mice are challenged by
H.pylori, greater colonization of H.pylori in mutant mice
are formed than in WT mice, suggesting that the muta-
tion in MHC II on APC cells fails on the presentation of
epitopes peptides. The level of anti H.pylori antibody in
challenged wild-type mice is high but not detectable in
mutant mice. Moreover, oral immunization with H.pylori
whole-cell lysates reduced infection in wild-type and
MHC I -/- mice but not in MHC II -/- mice [1]. All thesehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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role in protection of H.pylori infection.
Antibiotic treatment is the most effective therapy for
H.pylori infection. Unfortunately, this strategy often
results in many side-effects, such as poor patient com-
pliance, production of antibiotic resistant strain and re-
infection. Recently, developing effective vaccines against
H.pylori has attracted much attention. Epitope-based
vaccine design (EBVD) represents an alternative way to
improve native antigen which can not evoke optimal im-
mune response to pathogen [2]. The conserved epitopes
identified by EBVD have been shown to not only elicit
specific immune response but also increase potency and
breadth of immune response. One of the key steps in
EBVD approach is the identification of appropriate epi-
topes to obtain effective response.
Lpp20 is an outer membrane lipoprotein of H.pylori
and also sheds from surface to medium [3,4]. Lpp20 is
one of major antigens recognized by rabbit antiserum
against H.pylori [5]. Passive anti-Lpp20 antibody transfu-
sion decreases H.pylori infection in H. pylori infected
mice [3]. Therefore, Lpp20 is an excellent vaccine candi-
date antigen for H.pylori infection.
In this study, we hypothesized that modified candidate
antigens of Lpp20 may trigger more effective immune
response induced by H.pylori infection. Two identified
peptides on Lpp20 were able to stimulate CD4+ T cell
proliferation and additive secretion of IFN-γ. These
results provide us better understanding of cellular im-
munity against H.pylori infection and insights into the
design of H.pylori vaccines.
Methods
Prediction and synthesis of Lpp20 Th cell epitopes
Amino acid sequence of Lpp20 for H.pylori strain
NCTC11639 was acquired from NCBI protein database
(No. AAZ13599 submitted by us [6]). For BALB/c mice,
MHC II molecule includes I-Ad and I-Ed types. Potential
I-Ad and I-Ed restricted Th cell epitopes of Lpp20 were
predicted by SYFPEITHI system [7]. Five highest-scored
I-Ad restricted and five highest-scored I-Ed restricted pu-
tative epitopes were selected. After further analysis, eight
epitopes were synthesized by Chinese peptide Ltd.Co.
(Hangzhou, China). The peptides were supplied as lyso-
philized powder and dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 4 mg/ml, sterilized with
filter and stored in aliquots at −20°C. Peptides were
diluted with RMPI 1640 incomplete culture medium
(Gibco) before experiments. Recombinant Lpp20 (rLpp20)
was expressed in Escherichia coli previously [6].
Mice and immunization
Female BALB/c mice aged 6 ~ 8 weeks were purchased
from Experimental Animal Center of Southern MedicalUniversity and approval to conduct this study was
granted by the Ethics Committee of Southern Medical
University. For rLpp20 immunization, mice were admi-
nistered with 100 ug of rLpp20 emulsified in Complete
Freund’s adjuvant (CFA; Sigma) by subcutaneous route in
the four limbs and boosted 2 weeks later with the same
protein in incomplete Freund’s adjuvant (IFA; Sigma).
For peptides immunization, mice were administered
with 100ug of peptide in IFA using the same procedure.
Mice were used for experiments at 7–10 days after
immunization. Mice immunized with PBS were used as
control. Five mice were included in each group.
Preparation of antigen presenting cell (APC)
Mice were sacrificed and spleens were harvested. After
treatment with erythrocyte lysing buffer (0.83% NH4Cl2),
splenocytes were resuspended to 5 × 107 cells /ml in
PBS with the addition of 100 μl mitomycin-C (Sigma;
500 μg/ml in PBS). Then these cells were incubated for
20 min at 37°C followed by three washes with RPMI
1640. The supernatant was discarded and the pelleted
cells were resuspended in RPMI 1640 as APCs.
CD4+ T cells proliferation assay
Mice were euthanized and spleens were harvested after
the last immunization. Single-cell suspensions were
obtained by homogenizing spleens and passing cells
through a 70 mm cell strainer. The erythrocytes were
removed by Ammonium Chloride Lysing Reagent (BD
Biosciences, PharMingen). CD4+T cells were negatively
sorted using mouse CD4 negative isolation kit (Dynal).
Routinely, the resultant cells were >95% CD4+ T cell as
determined by flow cytometry. To stimulate CD4+ T
cells, peptides or rLpp20 were added into the mixture of
APCs (4 × 105) and CD4+ T cells (2 × 105) which were
resuspended in 200 μl RPMI-1640 complete cultured
(RPMI-1640, 10% fetal bovine serum, 2 mM glutamine,
100 U of penicillin/ml, 100 U of streptomycin/ml,
50 mM 2-mercaptoethanol, and 25 mM HEPES). Cul-
ture without any antigen was served as negative control.
Other controls were APCs without CD4+ T cells in the
presence of ConA and CD4+ T cells without APC in the
presence of peptides. Culture was set up in triplicate
and incubated at 37°C, 5% CO2 for 5 days. During the
final 16–18 h, each well was pulsed with 1 μCi of [3H]
thymidine (Amersham Biosciences, Piscataway, NJ).
[3H] thymidine incorporation was measured in a liquid
scintillation counter after collecting cells onto glass
fiber filters. The stimulation index (SI) was determined
by comparing [3H] thymidine incorporation in the
peptide-stimulated wells with unstimulated wells using
the following equation: SI = mean cpm of peptide wells/
mean cpm of no peptide wells. Experiments were inde-
pendently repeated three times. Proliferative response
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confidence level [8,9]. To investigate if there was any
additive or subtractive interaction among the identified
epitopes, the peptides were pooled to stimulate CD4+ T
cells from mice immunized with rLpp20.MHC restriction studies
To detect MHC restriction for presentation, mAbs
(eBiosciensce) against the murine I-Ad (clone 39-10-8),
I-Ed (clone14-4-4S), and MHC class I (H-2d) (clone
34-1-2S) molecules were added to cultures and their
capacity to inhibit peptide-specific proliferation were
measured. Briefly, purified CD4+ T cells from mice
primed with rLpp20 were preincubated with mAbs for
2 h at 37°C and then peptides(1.25 μg/ml) were added
and incubated at 37°C, 5% CO2 for 5 days. The prolif-
eration induced by peptides was tested as described
above. Culture incubated with peptides without mAb
served as negative control.Cytokine profile analysis by ELISA and real-time PCR
To detect the subset of CD4+ T cells, cytokine profile in
response to peptide L1 and L2 was analyzed. CD4+ T cell
culture supernatant (100 μl each) was collected after
72 h and cytokines were quantified by IFN-γ and IL-4
ELISA kits (eBioscience, San Diego, CA, USA). Cytokine
production was calculated from the titration of supplied
calibrated cytokines standards. Results were corrected for
dilution of the sample to yield concentration in pg/ml.
Meanwhile, mRNA expression level of IFN-γ and IL-4
were quantified. Total RNA from splenic lymphocytes was
isolated using Trizol RNA isolation kit (Roche). Real time
PCR was performed for IFN-γ, IL-4 and β-actin (as in-
ternal control) using SYBR Green Supermix in a 96-well
plate of the ABI Prism 7500 Fast Sequence Detector
(Applied Biosystems). 25 μl reaction mixtures contained
1 μl 100 X diluted cDNA, 12.5 μl 2X Power SYBR Master
Mix (Applied Biosystems) and 150 nM of each primer.
The primer sequences were listed as below:
IFN-γ: 50-TGTCATCCTGCTCTTCTTTCTC-3050-GACCTCAAACTTGGCAATACTC-30IL-4: 50-AACTCAAGTGGCATAGATGTGG-3050-GACCTCAAACTTGGCAATACTC-30β-actin: 50-ATCCGTAAAGACCTCTATGCCAACA-3050-GTCGCCTTCACCGTTCCAGTTT-30The relative fold change of mRNA level of IFN-γ and
IL-4 was calculated using the delta delta Ct (threshold
cycle) method [7]. The averages and standard deviations
were determined from triplicate datasets. ΔCt is thedifference between Ct of target mRNA and Ct of β-actin
for each group.
Flow cytometry analysis
Splenic lymphocytes stimulated with L1 and L2 respect-
ively were phenotyped by double staining with anti-CD4
and CD3 mAbs (eBiosciensce) and fluorescence acti-
vated cell sorter. One million cells were collected and
preincubated with rat IgG2b anti-mouse CD16/CD32
(clone 93, eBiosciensce) for 10 min to exclude unspecific
Fc-receptor-mediated binding. After washing in cold
PBS (2% bovine serum albumin), the cells were stained
with PE-labeled anti-CD4 (clone RM4-5) and FITC-
labeled anti-CD3 (clone 145-2C11) mAbs for 30 min on
ice. Unspecific staining was controlled with appropriate
FITC and PE labeled isotype controls respectively. The
samples were analyzed with FACS Calibur flow cyt-
ometer and the data were analyzed by CELLQuest soft-
ware (BD Biosciences).
Statistical analysis
Data were representative of three independent experi-
ments and expressed as mean ± standard deviation (SD).
The results were processed using Student’s t-test with
SPSS13.0 program. Significance was defined by a value
of P < 0.05.
Results
Eight Th cell epitopes on Lpp20 were synthesized
To study Th epitopes on Lpp20, the potential binding
motifs for I-Ad and I-Ed in amino acid sequence of
Lpp20 were predicted respectively. Five I-Ad restricted
and five I-Ed restricted epitopes were obtained (Table 1).
Since there was only one amino acid different between
residues 8 ~ 22aa and 7 ~ 21aa, the former was selected
as candidate peptide because of its higher score. Resi-
dues 58 ~ 72aa was both I⇀Ad and I⇀Ed restricted epi-
tope. Thus eight peptides were synthesized and named
as L1 ~ L8. The purities of these peptides were all >90%
except for L4 which was too hydrophobic to be mea-
sured (Table 1).
L1 and L2 epitopes stimulated CD4+ T cell proliferation
To identify Th cell epitopes on Lpp20, CD4+ T cells
from mice immunized with rLpp20 were isolated and
cultured with APCs and synthetic peptides. CD4+ T
cells, which were isolated from rLpp20-immunized mice
but not from PBS-treated mice, responded to L1, L2 and
rLpp20 (SI > 2, Figure 1A). CD4+ T cells without APCs
could not proliferate (SI < 2, Figure 1B). Thus, prolif-
erative CD4+ T cell response was antigen-specific since
the cells were primed by rLpp20 but not by PBS.
Furthermore, CD4+ T cells recognize antigenic epitopes
Table 1 Prediction and synthesis of potential CD4+ T cell epitopes on Lpp20
Name Residues Sequence MHC restriction Scores Theoretical Mr Actual Mr Purity (100%)
L1 83 ~ 97aa NQATAKARANLAANL I⇀Ad 32 1526.72 1526.7 93.5
L2 58 ~ 72aa Y E KY SGV F LGRAEDL I⇀Ad 30 1746.94 1746.9 93.0
L3 12 ~ 26aa SV IAAMV I VGC SHAP I⇀Ad 29 1454.77 1454.8 86.3
L4 8 ~ 22aa I LGM SV I AAMV I VGC I⇀Ad 26 1476.91 1476.9 Crude
7 ~ 21aa K I LGMSV I AAMV I VG I⇀Ad 24
L5 135 ~ 149aa K E L IAS KM LARYVGK I⇀Ed 22 1707.11 1707.1 95.6
L6 44 ~ 58aa APDVVGD L E K VAKY I⇀Ed 20 1689.93 1689.9 91.4
58 ~ 72aa Y E KY SGV FLGRAEDL I⇀Ed 20
L7 150 ~ 164aa DRV FV LVG LDKQ I VD I⇀Ed 20 1716.01 1716.0 90.7
L8 77 ~ 92aa D VDY STNQA TAKARA I⇀Ed 18 1610.78 1610.7 91.8
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L2 contain Th cell epitopes of Lpp20.
CD4+ T cells recognized L1 and L2 epitopes in the context
of MHC class II molecule
CD4+ T cells recognize peptides presented by MHC II
molecules on APCs. The interaction between CD4+ T
cells and the peptide-MHC II complex can be blocked
by mAbs against MHC II molecules. To determine the
specificity of restriction of L1 and L2, anti-MHC mAbs
namely I-Ad and I-Ed were incubated with APCs respect-
ively prior to antibody stimulation of Th cells. Pretreat-
ment of I-Ad specific mAb reduced cell proliferation
significantly after L1 and L2 peptides’ stimulation. Mean-
while, I-Ed specific mAb only inhibited Th cells prolif-
eration after L2 peptide stimulation but not L1 peptide.
These results suggested that CD4+ T cells recognized L1
and L2 epitopes in the context of MHC II molecules and
confirmed that L1 belonged to I- Ad restriction and L2
belonged to both I-Ad and I-Ed restriction. On contrast,
anti-MHC I mAbs had no effect on L1 and L2 stimu-
lated Th cells proliferation (Figure 2).Figure 1 Specific CD4+ T cell proliferation analysis revealed that L1 an
were tested in proliferative responses to synthetic peptides (1.25 μg/ml), rL
mice treated with PBS served as controls to determine if the responses we
Index (SI) of three independent experiments ± S.D. SI≥ 2 was considered a
in presence of APC. (B) CD4+ T cell did not response to peptides and rLpp
level.L1 and L2 epitopes both mainly secreted Th1 cytokines
To determine the subset of CD4+ T cells induced by L1
and L2 epitopes, cytokine profiles of CD4+ T cells in re-
sponse to L1 and L2 were analyzed by ELISA. CD4+ T
cells isolated from mice immunized with rLpp20 secreted
two folds more Th1 specific cytokine (e.g. IFN-γ) after
stimulation with L1 and L2 peptides compared with the
control. Moreover, the level of the secreted Th2 specific
cytokine IL-4 remained unchanged in the medium after
L1 and L2 stimulation, suggesting Th1 was activated
(Figure 3A).This observation was further confirmed in the
splenic lymphocytes from L1 and L2 immunized mice.
The mRNA level of IFN-γ was 1.5 fold change higher in
the splenic lymphocytes stimulation than controls while
the mRNA level of IL-4 remained unchanged upon L1
and L2 activation (Figure 3B). Therefore these results
demonstrated that L1 and L2 preferentially elicited a
polarized Th1-type response.
The identified two peptides interacted additively
To investigate if there was any additive or subtractive
interaction between L1 and L2 epitopes, we pooled thed L2 were epitopes of Lpp20. CD4+ T cells primed with rLpp20
pp20 (15 μ g/ml) and medium as control. CD4+ T cells isolated from
re rLpp20-specific. Responses were expressed as mean Stimulation
s positive. (A) CD4+ T cell only responded to peptide L1, L2 and rLpp20
20 in absence of APC. (*) SI is higher than 2 at the 95% confidence
Figure 2 Inhibition of Th cells proliferation by MHCII-specific mAbs. Purified CD4+ T cells from mice primed with rLpp20 were stimulated
with peptides (1.25 μg/ml) in the presence of mAbs specific for I-Ad, I-Ed, or MHCImolecules. Cultures incubated with peptides without mAbs
were used as controls. The proliferation of the cells was quantified in triplicate by 3H-TdR incorporation. The values shown were means ± SD of
three independent experiments.
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responses to the pooled peptides versus individual peptide.
The pooled peptides stimulated significantly more ele-
vated Tcell response than each peptide (P < 0.05, Figure 4).
Thus there is an additive interaction between the two
peptides.
CD4+ T cell from mice immunized with identified two
epitopes exhibited proliferation
Having identified two Th cell epitopes on Lpp20, we then
evaluated whether lymphocytes primed by L1 and L2
could recognize naturally processed antigen. For this pur-
pose, we immunized mice with two peptides emulsified in
IFA respectively and assessed the response of CD4+ T cells
in vitro. T cells from mice immunized with L1 or L2
exhibited significant proliferation upon stimulation withpeptides peptides
A
Figure 3 Cytokine profile of splenic lymphocytes in response to pept
were incubated with each peptide for 72 h and cytokines in the culture su
antigen was used as control. Results were expressed as means ± S.D. of trip
from control was indicated by *(p < 0.05). (B) CD4+ T cells from mice immu
IL-4 were determined by real-time PCR and fold changes calculated using
with PBS in IFA were served as negative controls. The values shown were m
control group was indicated by * (p < 0.05).L1, L2 and rLpp20 respectively in vitro (SI > 2, Figure 5).
Under the same conditions, T cells from IFA without
peptides-immunized mice did not respond to any peptide
and rLpp20 (SI < 2, Figure 5A). This result suggested that
Th1 cells induced by either L1 or L2 had responded to
native antigen rLpp20. The FACS analyses were also per-
formed to determine the relative percentage of CD4+
CD3+ T cells immunized with L1 and L2 respectively.
The percentage of CD4+ CD3+ T cells from mice immu-
nized with L1 and L2 were higher than control (P < 0.05,
Figure 5B). These results confirmed again that L1 and L2
stimulated CD4+ T cells proliferation.
Discussion
CD4+ T cells recognize antigenic epitopes in the context
of MHC II molecules on APCs. Many investigations ofcytokines
B
ide L1 and L2. (A) CD4+ T cells from mice immunized with rLpp20
pernatants were measured by sandwich ELISA. Medium without any
licate wells from three independent experiments. Significant difference
nized with peptide L1 and L2 was isolated. Relative levels of IFN-γ and
the delta delta Ct method. CD4+ T cells isolated from mice treated
eans ± SD of three experiments. Significant difference from PBS
Figure 4 Synergistic interaction of CD4+ T cell proliferation between two epitopes. CD4+ T cells primed with rLpp20 were tested in a
proliferation assay for responses to peptide L1, L2, pooled L1 and L2 (1.25 μg/ml) and rLpp20 (15 μ g/ml). Response to the antigen was expressed
as the mean SI of three independent experiments ± S.D. The medium with rLpp20 was served as positive control and without any antigen weas
used as negative control. The pooled peptides was significantly different from individual peptide (*p < 0.05). The values shown were means ± SD
of three experiments.
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immune response is mediated by CD4+ T cells but not
by CD8+ T cells. Therapeutic immunization reduced
H.pylori colonization in stomach in mice lacking B cells,
suggesting that T cell is protective [10]. Oral immu-
nization with H. pylori whole-cell lysates reduced infection
in wild-type and MHC I -/- mice, but it had no effect on
MHC II -/- mice. Anti-H.pylori antibody levels in serum
showed a dominant IgG in immunized wild-type and MHC
I -/- mice but no detectable IgG in MHCII-/- mice [1].Figure 5 Specific CD4+ T cell responses in mice immunized with pept
peptides were tested in proliferative responses to peptide L1 and L2 (1.25
from mice treated with PBS in IFA were served as negative controls. Respo
experiments ± S.D. (*) SI was higher than 2 at the 95% confidence level. SI≥
determine the relative percentage of CD4+ CD3+ T cells immunized with p
emulsified in IFA. All data were reported as means ± SD of three experimenCD4+T cells from H.pylori antigen immunized mice
were sufficient to transfer protective immunity to the
immunodeficient recipients [11]. Taken together, identi-
fication and characterization of the Th cell eptioptes of
Lpp20 would contribute to a better understanding of
protective immunity to H.pylori and facilitate the devel-
opment of effective immunotherapeutic and immuno-
prophylactic strategies.
The identification of CD4+ T epitiopes has tradition-
ally been done either by sequencing of eluted peptideside L1 and L2. (A) CD4+ T cells immunized with Lpp20-derived
μg/ml), rLpp20 (15 μg/ml) and control medium. CD4+ T cells isolated
nse to the antigen was expressed as mean SI of three independent
2 was considered as positive. (B) FACS analyses were performed to
eptide L1 and L2 respectively. Control group was immunized with PBS
ts. *p < 0.05 vs. control.
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screening panels of overlapping peptides. These two
methods were successfully performed to identify many T
epitopes; however, the method of sequencing eluted pep-
tide is potentially cumbersome to identify epitopes from
multiple processed antigens but not specifically a single
antigen. The overlapping peptide method needs synthe-
sis of a series of overlapping peptides, thus making it an
expensive, laborious and time-consuming process. In
addition, this method possibly misses junctional epitopes
that might be present in the overlapping regions, though
spanning the entire length of the antigens [12]. These
considerations lead us to use the combination of prediction
and experiments to identify Th cell epitopes. Although it
is possible to miss potential epitopes, this method repre-
sents a quick and effective approach to identify epitopes.
Here we used algorithm program with T cell biological
analysis to identify Th cell epitopes on Lpp20. Eight epi-
topes were selected to be synthesized and measured, of
which two (L1 and L2) were identified to be Th cell epi-
topes, which were located at residues 83-97aa (L1) and
58-72aa (L2). Interestingly, L2, which was predicted to
be both restricted by I-Ad and I-Ed, effectively stimu-
lated more proliferation of splenic CD4+ T cells than L1,
which was predicted to be I-Ad restriction. Our results
indicate that the combination of prediction and experi-
ments is an easy and effective way to identify Th cell
epitopes. The present findings may be valuable for the
development of epitope-based vaccines against H.pylori.
CD4+ T cells can polarize to Th1 or Th2 cells based
on their profile of cytokine. Th1 cells produce IFN-γ,
IL-2 and TNF-β that mediate cellular immunity. In con-
trast, Th2 cells produce IL-4, IL-5, IL-10 and IL-13,
which are responsible for humoral immunity [13]. It is
generally believed that polarized Th1-type response is
involved in the pathogenesis of H.pylori infection [14-17].
But Whether Th1 or Th2 type immune response is re-
sponsible for protective immunity is still unclear. Some
studies support that Th2 response characterized by IL-4
secretion is important to clear H.pylori [18-21]. On the
contrary, some studies reveal that protection against H.
pylori is mediated by predominantly Th1-type immune
responses independent of IL-4 [22,23]. Moreover, some
researchers demonstrate that a mixed Th1-Th2 phenotype
is correlated with the protective immunity against H.pylori
infection [24]. Therefore, identification of Th1 and Th2
type epitopes may help us investigate the role of Th1 or
Th2 type responses on pathogenesis and immunity of
H.pylori infection. Meanwhile, it is also a pivotal step
for a rational modulation of immune response by devel-
oping effective multiple Th1 or/and Th2 epitope vac-
cine. In this study, we found that L1 and L2 were both
Th1-type epitopes and induced CD4+ T cell to mainly
secrete IFN-γ.In conclusion, we have identified two Th1 cell epitopes
on Lpp20. Peptide L1 is I-Ad restricted epitope and pep-
tide L2 is both I-Ad and I-Ed restricted epitopes. These
two peptides both evoked Th1-type response. In addition,
the two pooled peptides stimulated significantly more
elevated T cell responses, showing an additive effect. We
have identified one B cell epitope of Lpp20 using phage
displayed library previously [6]. Next, we will combine
these two Th epitopes and one B cell epitope to evaluate
whether the combined epitopes can induce protective
response and prevent H.pylori infection better than the
whole Lpp20 protein in BALB/c mice. The data from our
mouse model will provide significant information for fur-
ther study of epitope-based vaccine.
Conclusions
We identified two H-2d restricted CD4+ T cell epitopes
of H.pylori Lpp20, which interacted additively and
mainly secreted INF-γ and belonged to Th1 type epi-
topes. Immunization with the identified epitopes primed
antigen-specific CD4+ cell response. These data provide
useful insights regarding immunity against H.pylori and
have the potential to guide the design of epitope-based
vaccines.
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